https://www.advanzpharma.com/product-risk-materials/aflibercept2026-04-30weekly1.0https://www.advanzpharma.com/product-risk-materials/golimumab2026-02-27weekly1.0https://www.advanzpharma.com/product-risk-materials/deferiprone2025-02-14weekly1.0https://www.advanzpharma.com/product-risk-materials/vernakalant2024-06-18weekly1.0https://www.advanzpharma.com/product-risk-materials/omega-3-acid-ethyl-ester2024-01-16weekly1.0https://www.advanzpharma.com/product-risk-materials/levothyroxine2023-06-15weekly1.0https://www.advanzpharma.com/product-risk-materials/lenalidomide2022-10-25weekly1.0https://www.advanzpharma.com/product-risk-materials/digoxin2021-11-19weekly1.0https://www.advanzpharma.com/product-risk-materials/chloromycetin2021-05-17weekly1.0https://www.advanzpharma.com/product-risk-materials/emtricitabine-tenofovir2021-03-15weekly1.0https://www.advanzpharma.com/product-risk-materials/levofloxacin2021-03-10weekly1.0https://www.advanzpharma.com/product-risk-materials/carbimazole2021-03-10weekly1.0https://www.advanzpharma.com/product-risk-materials/methotrexate2021-03-10weekly1.0